T1	p 77 106	anemic patients with cancer .
T2	p 284 301	Eligible patients
T3	p 571 654	Three hundred sixty-five patients were enrolled . One hundred eighty-three patients
T4	i 126 217	maintenance epoetin alfa administered once every 3 weeks with continued weekly epoetin alfa
T5	i 372 465	epoetin alfa 40,000 U subcutaneously ( SC ) , followed by either standard weekly epoetin alfa
T6	i 494 506	epoetin alfa
T7	i 1544 1565	epoetin alfa 40,000 U
T8	i 1734 1765	continued weekly epoetin alfa .
T9	o 1170 1261	mean end-of-study Hb levels . Toxicities , including thromboembolism , and overall survival
T10	o 1314 1344	global quality of life ( QOL )
T11	o 1426 1448	global QOL improvement